SynthesisJournal of medical screening2024
Strong association between reduction of late-stage cancers and reduction of cancer-specific mortality in meta-regression of randomized screening trials across multiple cancer types.
Synthesis in Journal of medical screening, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Late-Stage Outcomes as Surrogates for Mortality in Cancer Screening Trials: A Systematic Review and Meta-analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Pooled it
- Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials.Statistics in medicine · 2026Article
- Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.PharmacoEconomics · 2026Review
- UK National Screening Committee position statement on surrogate outcomes in cancer screening trials.BMJ (Clinical research ed.) · 2026Article
- Challenges in the future of cancer screening.International journal of cancer · 2026Review
- Evaluating the basis for use of advanced stage as a surrogate endpoint for cancer mortality in screening trials: a simulation study of meta-correlation and an alternative framework.EClinicalMedicine · 2026Article
- The National Health Service-Galleri multicancer screening trial: explanation and justification of unique and important design issues.Journal of the National Cancer Institute · 2026Article
- Measuring and defining screening benefit in a new era of cancer early detection.Journal of the National Cancer Institute · 2026Article
- Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points.JAMA network open · 2025Article
- Promises and pitfalls of multi-cancer early detection using liquid biopsy tests.Nature reviews. Clinical oncology · 2025Review
- Article
- Modeled Benefit of Individual Cancer Signal Origin Prediction for Multi-Cancer Early Detection.Cancer research communications · 2025Article
- Understanding the risk of ionizing radiation in breast imaging: Concepts and quantities, clinical importance, and future directions.European journal of radiology · 2024Review
- Deceptive Measures of "Success" in Early Cancer Detection.Current oncology (Toronto, Ont.) · 2024Review
- Alternative endpoints to mortality in cancer screening trials.Molecular oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLate-stage cancer incidence has been proposed as an early surrogate for mortality in randomized controlled trials (RCTs) of cancer screening; however, its validity has not been systematically evaluated across screening RCTs of different cancers.
methodsWe conducted a meta-regression analysis of cancer screening RCTs that reported both late-stage cancer incidence and cancer mortality. Based on a systematic literature review, we included 33 RCTs of screening programs targeting seven cancer types, including lung (
resultsAcross cancer types, the relative reduction of late-stage cancer incidence was linearly associated with the relative reduction of cancer mortality. Specifically, we observed this association for lung (
conclusionsMeta-regression of historical screening RCTs showed a strong linear association between reductions in late-stage cancer incidence and cancer mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.